Related Experiment Video
Updated: Nov 25, 2025
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
Puerarin alleviates coronary heart disease via suppressing inflammation in a rat model
Liangping Zhao1, Li Wang1, Daimin Zhang2
1Department of Cardiology, The Second Affiliated Hospital of Soochow University, Gusu District, Suzhou, Jiangsu Province 215004, China.
Insights
Puerarin effectively treats coronary heart disease (CHD) in rats by reducing inflammation and improving cardiac function. This study suggests Puerarin as a potential therapeutic agent for CHD treatment.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Puerarin demonstrates anti-inflammatory properties relevant to chronic heart failure (CHF).
- The efficacy of Puerarin in treating coronary heart disease (CHD) requires further investigation.
Purpose of the Study:
- To evaluate the therapeutic effects of Puerarin on a rat model of coronary heart disease (CHD).
- To investigate the underlying mechanisms of Puerarin's action in CHD, focusing on inflammation and cardiac function.
Main Methods:
- A rat model of CHD was established.
- Serum parameters, cardiac enzyme levels (CK, CK-MB, LDH, cTnT), and cardiac function were assessed.
- Histological examination, apoptosis assays (TUNEL), gene/protein expression analysis (qRT-PCR, Western blot) were performed.
Main Results:
- CHD rats exhibited dyslipidemia, elevated inflammatory markers (MMP-9, CD40L, TNF-α, CRP), cardiac damage, and apoptosis.
- Puerarin treatment reversed these pathological changes, suppressed NF-κB, and modulated key signaling pathways (FXR, AKT, STAT3).
Conclusions:
- Puerarin alleviates CHD in a rat model by inhibiting inflammation.
- These findings support Puerarin as a potential therapeutic strategy for treating coronary heart disease.
Background:
Puerarin shows inhibitory effects on inflammation in chronic heart failure (CHF), but its efficacy in coronary heart disease (CHD) remained vague.
Methods:
Rat CHD model was constructed, and serum parameters were determined using a blood liquid biochemical analyzer. Also, contents of creatine kinase (CK), creatine kinase MB isoenzyme (CK-MB), lactate dehydrogenase (LDH) and cardiac troponin (cTnT) were measured using colorimetry. Histological examination was conducted with Hematoxylin-Eosin (H&E) staining, and cardiac function was assessed by Echocardiography. Cell apoptosis was detected using Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Relative expressions were measured using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot as needed.
Results:
In CHD rats, the levels of TC, LDL and TG and the expressions of matrix metalloproteinase-9 (MMP-9), CD40 ligand (CD40L), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) were increased while HDL level was decreased, accompanied with inflammatory cell infiltration and cardiac malfunction. Also, the contents of CK, CK-MB, LDH and cTnT, the percentage of apoptotic cells, the expressions of Bcl-2 associated X protein (Bax), cleaved Caspase-3, TNF-α, Interleukin-β (IL-β), IL-6 and Lipoprotein-associated Phospholipase A2 (Lp-PLA2) expressions and the levels of oxidized-(ox-)LDL and malondialdehyde (MDA) were upregulated, while the level of super oxidase dismutase (SOD) and the expressions of B cell lymphoma-2 (Bcl-2) and vascular endothelial growth factor (VEGF) were downregulated. However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)κB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).
Conclusion:
Puerarin alleviated CHD in rats via inhibiting inflammation, providing possible method for CHD treatment.
